St. Jude pioneered
the use of hydroxyurea to treat sickle cells in children.
In an accompanying editorial, Debra L. Weiner and Carlo Brugnara of Harvard Medical School call for increased
use of hydroxyurea.
Not exact matches
Rather than calculating a standard dose
of hydroxyurea based on patients» weight, researchers
used a dose - escalation approach to determine the maximum tolerated dose for each
of the 230 St. Jude patients enrolled in the study.
Also lacking has been evidence
of overall improved patient outcomes if
hydroxyurea is
used to increase blood levels
of fetal hemoglobin to more than 20 percent.
Recently, drugs such as 5 -
hydroxyurea have been
used to treat meningiomas, but as yet there are no data on the efficacy
of this approach.